Structural alterations based on naproxen scaffold: Synthesis, evaluation of antitumor activity and COX-2 inhibition, and molecular docking
作者:Walaa M. El-Husseiny、Magda A.-A. El-Sayed、Naglaa I. Abdel-Aziz、Adel S. El-Azab、Yousif A. Asiri、Alaa A.-M. Abdel-Aziz
DOI:10.1016/j.ejmech.2018.09.007
日期:2018.10
testing showed that the compounds 4b, 6c, 10b, and 10c exhibited effective COX-2 inhibition, with IC50 values of 0.40–1.20 μM, and selectivity index (SI) values of >62.50–20.83, using celecoxib as a reference drug (IC50 = 0.11 μM; COX-2 SI: >227.20). Compounds 6c and 10c, which were potent COX-2 inhibitors, were docked into the COX-2 binding site, where these compounds exhibited strong interactions.
一系列新的非羧酸萘普生类似物中,轴承的各种环体系,如恶二唑的3A-C和6A-C ,环烷烃图4a-d ,环状酰亚胺5A-C ,和三唑7 - 9和图10A-C ,是合成的。此外,在体外抗肿瘤活性和环加氧酶的同功酶(COX-1 / COX-2)靶的抑制试验化合物3 - 10进行了研究。抗肿瘤活性测定的结果表明化合物4b,6c,10b和10c对被测细胞系MCF-7,MDA-231,HeLa和HCT-116表现出最大的抗肿瘤活性,IC 50范围为4.83–14.49μM。相比之下,参考药物阿霉素,阿法替尼和塞来昔布的IC 50值分别为3.18–26.79、6.20–11.40和22.79–42.74μM。此外,体外COX-1 / COX-2抑制试验表明,化合物4b,6c,10b和10c表现出有效的COX-2抑制作用,IC 50值为0.40–1.20μM,选择性指数(SI)值为> 62.50–20.83,使用塞来昔布作为参考药物(IC